Rationale: The cellular and molecular landscape and translational value of commonly used models of pulmonary arterial hypertension (PAH) are poorly understood. Single-cell transcriptomics can enhance molecular understanding of preclinical models and facilitate their rational use and interpretation. Objectives: To determine and prioritize dysregulated genes, pathways, and cell types in lungs of PAH rat models to assess relevance to human PAH and identify drug repositioning candidates. Methods: Single-cell RNA sequencing was performed on the lungs of monocrotaline (MCT), Sugen-hypoxia (SuHx), and control rats to identify altered genes and cell types, followed by validation using flow-sorted cells, RNA in situ hybridization, and immunofluorescence. Relevance to human PAH was assessed by histology of lungs from patients and via integration with human PAH genetic loci and known disease genes. Candidate drugs were predicted using Connectivity Map.Measurements and Main Results: Distinct changes in genes and pathways in numerous cell types were identified in SuHx and MCT lungs. Widespread upregulation of NF-κB signaling and downregulation of IFN signaling was observed across cell types. SuHx nonclassical monocytes and MCT conventional dendritic cells showed particularly strong NF-κB pathway activation. Genes altered in SuHx nonclassical monocytes were significantly enriched for PAH-associated genes and genetic variants, and candidate drugs predicted to reverse the changes were identified. An open-access online platform was developed to share single-cell data and drug candidates (http://mergeomics.research.idre.ucla.edu/PVDSingleCell/).Conclusions: Our study revealed the distinct and shared dysregulation of genes and pathways in two commonly used PAH models for the first time at single-cell resolution and demonstrated their relevance to human PAH and utility for drug repositioning.
Rationale: The cellular and molecular landscape and translational value of commonly used models of pulmonary arterial hypertension (PAH) are poorly understood. Single-cell transcriptomics can enhance molecular understanding of preclinical models and facilitate their rational use and interpretation. Objectives: To determine and prioritize dysregulated genes, pathways, and cell types in lungs of PAH rat models to assess relevance to human PAH and identify drug repositioning candidates. Methods: Single-cell RNA sequencing was performed on the lungs of monocrotaline (MCT), Sugen-hypoxia (SuHx), and control rats to identify altered genes and cell types, followed by validation using flow-sorted cells, RNA in situ hybridization, and immunofluorescence. Relevance to human PAH was assessed by histology of lungs from patients and via integration with human PAH genetic loci and known disease genes. Candidate drugs were predicted using Connectivity Map.Measurements and Main Results: Distinct changes in genes and pathways in numerous cell types were identified in SuHx and MCT lungs. Widespread upregulation of NF-κB signaling and downregulation of IFN signaling was observed across cell types. SuHx nonclassical monocytes and MCT conventional dendritic cells showed particularly strong NF-κB pathway activation. Genes altered in SuHx nonclassical monocytes were significantly enriched for PAH-associated genes and genetic variants, and candidate drugs predicted to reverse the changes were identified. An open-access online platform was developed to share single-cell data and drug candidates (http://mergeomics.research.idre.ucla.edu/PVDSingleCell/).Conclusions: Our study revealed the distinct and shared dysregulation of genes and pathways in two commonly used PAH models for the first time at single-cell resolution and demonstrated their relevance to human PAH and utility for drug repositioning.
Entities:
Keywords:
Sugen-hypoxia; drug repurposing; monocrotaline; pulmonary hypertension; single-cell RNA sequencing
Authors: Raymond L Benza; Dave P Miller; Robyn J Barst; David B Badesch; Adaani E Frost; Michael D McGoon Journal: Chest Date: 2012-08 Impact factor: 9.410
Authors: Sébastien Bonnet; Steeve Provencher; Christophe Guignabert; Frédéric Perros; Olivier Boucherat; Ralph Theo Schermuly; Paul M Hassoun; Marlene Rabinovitch; Mark R Nicolls; Marc Humbert Journal: Am J Respir Crit Care Med Date: 2017-03-01 Impact factor: 21.405
Authors: Javier Milara; Juan Escrivá; José Luis Ortiz; Gustavo Juan; Enrique Artigues; Esteban Morcillo; Julio Cortijo Journal: Eur Respir J Date: 2016-03-23 Impact factor: 16.671
Authors: Chris Happé; Kondababu Kurakula; Xiao-Qing Sun; Denielli da Silva Goncalves Bos; Nina Rol; Christophe Guignabert; Ly Tu; Ingrid Schalij; Karien C Wiesmeijer; Olga Tura-Ceide; Anton Vonk Noordegraaf; Frances S de Man; Harm Jan Bogaard; Marie-José Goumans Journal: Cells Date: 2020-06-08 Impact factor: 6.600
Authors: Didem Saygin; Tracy Tabib; Humberto E T Bittar; Eleanor Valenzi; John Sembrat; Stephen Y Chan; Mauricio Rojas; Robert Lafyatis Journal: Pulm Circ Date: 2020-02-28 Impact factor: 3.017
Authors: Greg Finak; Andrew McDavid; Masanao Yajima; Jingyuan Deng; Vivian Gersuk; Alex K Shalek; Chloe K Slichter; Hannah W Miller; M Juliana McElrath; Martin Prlic; Peter S Linsley; Raphael Gottardo Journal: Genome Biol Date: 2015-12-10 Impact factor: 13.583
Authors: Yang-Yang He; Xin-Mei Xie; Hong-Da Zhang; Jue Ye; Selin Gencer; Emiel P C van der Vorst; Yvonne Döring; Christian Weber; Xiao-Bin Pang; Zhi-Cheng Jing; Yi Yan; Zhi-Yan Han Journal: Front Pharmacol Date: 2021-11-05 Impact factor: 5.810
Authors: Julie Rodor; Shiau Haln Chen; Jessica P Scanlon; João P Monteiro; Axelle Caudrillier; Sweta Sweta; Katherine Ross Stewart; Alena Shmakova; Ross Dobie; Beth E P Henderson; Kevin Stewart; Patrick W F Hadoke; Mark Southwood; Stephen D Moore; Paul D Upton; Nick W Morrell; Ziwen Li; Stephen Y Chan; Adam Handen; Robert Lafyatis; Laura P M H de Rooij; Neil C Henderson; Peter Carmeliet; Ana Mishel Spiroski; Mairi Brittan; Andrew H Baker Journal: Cardiovasc Res Date: 2022-08-24 Impact factor: 13.081